Cyclin-dependent kinases (CDK) have recently attracted interest as targets for cancer therapy, e.g., CDK-5 as a mediator of transforming growth factor (TGF)-β signaling and programmed death ligand 1 expression,6,7 CDK-7 as a transcriptional regulator,8,9 and CDK-9 for its control of c-myc expression.10